Chemotherapy and cognition: comprehensive review on doxorubicin-induced chemobrain Sara Emad El-AgamyAmal Kamal Abdel-AzizSamar S. Azab Review Article 06 April 2019 Pages: 1 - 14
Uveal melanoma: physiopathology and new in situ-specific therapies E. B. SoutoA. ZielinskaA. M. Silva Review Article 11 May 2019 Pages: 15 - 32
Platinum-free interval affects efficacy of following treatment for platinum-refractory or -resistant ovarian cancer Mayumi Kobayashi-KatoMayu YunokawaKenji Tamura Original Article 13 April 2019 Pages: 33 - 39
Sunitinib in pediatric patients with advanced gastrointestinal stromal tumor: results from a phase I/II trial Arnauld C. VerschuurViera BajčiováKatherine A. Janeway Original Article Open access 20 April 2019 Pages: 41 - 50
Resistance models to EGFR inhibition and chemotherapy in non-small cell lung cancer via analysis of tumour size dynamics Hitesh B. MistryGabriel HelmlingerJames Yates Original Article Open access 24 April 2019 Pages: 51 - 60
Monomethyl auristatin E-conjugated anti-EGFR antibody inhibits the growth of human EGFR-positive non-small cell lung cancer Zhuanglin LiMingxue WangXuejing Yao Original Article 29 April 2019 Pages: 61 - 72
Pharmacokinetics and safety of lobaplatin plus etoposide in Chinese men older than 65 years with extensive-stage small cell lung cancer: a phase II clinical trial Jianhua ChenBingyang LiuPeng Zhang Original Article 30 April 2019 Pages: 73 - 81
Population pharmacokinetics of PF-05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin®) in patients with HER2-positive metastatic breast cancer Xiaoying ChenCheryl LiDonghua Yin Original Article Open access 03 May 2019 Pages: 83 - 92
A single-center, open-label study investigating the excretion balance, pharmacokinetics, metabolism, and absolute bioavailability of a single oral dose of [14C]-labeled idasanutlin and an intravenous tracer dose of [13C]-labeled idasanutlin in a single cohort of patients with solid tumors Zsuzsanna PápaiLin-Chi ChenJianguo Zhi Original Article 06 May 2019 Pages: 93 - 103
Orally administered salecan ameliorates methotrexate-induced intestinal mucositis in mice Yan GaoQi SunJianfa Zhang Original Article 08 May 2019 Pages: 105 - 116
Treatment with selenium-enriched Saccharomyces cerevisiae UFMG A-905 partially ameliorates mucositis induced by 5-fluorouracil in mice Bárbara A. A. PortoCinthia F. MonteiroFlaviano S. Martins Original Article 11 May 2019 Pages: 117 - 126
Clinical characteristics, treatment patterns and outcomes of patients older than 80 years diagnosed with DLBCL in China over a 10-year period Zhan ShiXi TangJie Zhuang Original Article 13 May 2019 Pages: 127 - 137
Inter- and intra-patient variability in pharmacokinetics of abiraterone acetate in metastatic prostate cancer Malmaruha ArasaratnamMegan CrumbakerHoward Gurney Original Article 13 May 2019 Pages: 139 - 146
Olanzapine-containing antiemetic therapy for the prevention of carboplatin-induced nausea and vomiting Kazuki TanakaNaoki InuiTakafumi Suda Original Article 13 May 2019 Pages: 147 - 153
Gemcitabine plus cisplatin versus fluorouracil plus cisplatin as a first-line concurrent chemotherapy regimen in nasopharyngeal carcinoma: a prospective, multi-institution, randomized controlled phase II study Xiang-Yun KongJian-Xun LuWei Jiang Original Article 13 May 2019 Pages: 155 - 161
A phase 2 study to assess the pharmacokinetics and pharmacodynamics of CPX-351 and its effects on cardiac repolarization in patients with acute leukemias Tara L. LinLaura F. NewellArthur C. Louie Original Article Open access 16 May 2019 Pages: 163 - 173
Pharmacokinetics of trastuzumab emtansine (T-DM1) as a single agent or in combination with pertuzumab in HER2-positive breast cancer patients with recurrent or locally advanced metastatic breast cancer Dan LuChunze LiSandhya Girish Original Article 17 May 2019 Pages: 175 - 185
Long non-coding RNA GHET1 contributes to chemotherapeutic resistance to Gemcitabine in bladder cancer Bo LiDalon XieHui Zhang Original Article 21 May 2019 Pages: 187 - 194
Renin–angiotensin system inhibitors for countering proteinuria induced by angiogenesis inhibitors: a retrospective observational analysis Toshinori HiraiYukari ShujiToshimasa Itoh Original Article 23 May 2019 Pages: 195 - 202
Clinical implications of an analysis of pharmacokinetics of crizotinib coadministered with dexamethasone in patients with non-small cell lung cancer Swan LinDana J. NickensWeiwei Tan Original Article 24 May 2019 Pages: 203 - 211
Qualitative and quantitative variations in liver function thresholds among clinical trials in cancer: a need for harmonization Edwin WangFei SongPaul Mathew Short Communication 22 April 2019 Pages: 213 - 216
Development of cutaneous squamous cell carcinoma after prolonged exposure to pegylated liposomal doxorubicin and hand–foot syndrome: a newly recognized toxicity Daniel F. PeaseBruce A. PetersonKeith M. Skubitz Short Communication 30 April 2019 Pages: 217 - 221
Efficacy of immunotherapy, gut microbiota and impact of antibiotic use: are there confounding factors? G. Milano Letter to the Editor 12 April 2019 Pages: 223 - 224
Stress resilience and survival among cancer patients: is there any absolute truth? Raffaella Mormile Letter to the Editor 30 April 2019 Pages: 225 - 226
